ANDREA BOLEY: Open Payments
NPI 1083070346 · NEW HAVEN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$278 in 16 payments from 11 companies in 2025. Trend: 2023 $276 · 2024 $396 · 2025 $278
Food & beverage: $278
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $51 |
| ABBVIE INC. | 3 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Lilly USA, LLC | 2 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
| PFIZER INC. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: Veozah, VRAYLAR, CAPLYTA, MOUNJARO, GEMTESA, Korlym, UBRELVY, HETLIOZ.
Industry payments across IN — which companies pay providers there.
